01 maj: Verdens måske fineste skjorter kommer til Danmark
07 maj: 10 aktier til den langsigtede portefølje
04-05-2012 12:55:05

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland

Actelion Pharmaceuticals Ltd /

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2011 - At today's Annual General Meeting of Actelion Ltd (SIX: ATLN), held in Basel Switzerland, shareholders voted on a number of resolutions put forward by the Company's Board.

The meeting was attended by 339 shareholders, representing 56'756'369 shares or 43.31% of the total outstanding shares.

On behalf of the Board and all employees of Actelion, the Chairman of the Board, Jean-Pierre Garnier, thanked the departing Board member and long-serving Chairman of Actelion, Robert C. Cawthorn for his services.

Jean-Pierre Garnier, Chairman of the Board of Directors at Actelion, commented: "When Robert Cawthorn was elected as Chairman of Actelion, he brought with him an incredible amount of experience in life science."

Jean-Pierre Garnier concluded: "Two distinguishing features have characterized Rob's leadership as Chairman: First, and foremost, his strategic vision on how to transform innovation into a successful global business opportunity. Secondly, he made himself available to management to share his experience, not only as Chairman but also as coach and mentor. Rob's unwavering commitment to the company and shareholders earned the respect of all of us."

The shareholders approved the Business Report consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts for the year 2011.

A proposal by the Board to distribute as a dividend, out of legal reserve originating from capital contribution, in the amount of CHF 0.80 per registered share was passed by the shareholders.

Actelion's shareholders endorsed the Compensation Report through a non-binding consultative vote.

The shareholders granted discharge to all members of the Board of Directors and of Senior Management.

A proposal by the Board to approve the reduction of the share capital by means of cancellation of the corresponding number of repurchased shares, as well as the amendment of the respective provision in the Company's Articles of Association, was passed by the shareholders.

Actelion's shareholders voted to re-elect Mr. Michael Jacobi to the Board for a term of three years.

The shareholders also voted to elect a new Director, Prof. Dr. Peter Gruss, to the Board for a term of three years.

Following the AGM, Actelion's Board comprises a total of ten members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, Carl Feldbaum, Peter Gruss, Werner Henrich, Michael Jacobi, Armin Kessler, and Jean Malo.

Finally, the shareholders confirmed Ernst & Young as the Company's statutory auditors for the year 2012.

###

Notes to the Editor

About Professor Gruss

Peter Gruss has been President of the Max Planck Society since 2002. He became a Scientific Member of the Max Planck Society in 1986, when he was appointed as Director at the Max Planck Institute for Biophysical Chemistry in Göttingen. He earned his PhD in biology at the University of Heidelberg and is honorary professor at the University of Göttingen.

Peter Gruss began his scientific career as a research assistant at the Institute for Virus Research in Heidelberg in 1977. From there, he moved on to the National Institutes of Health in Bethesda, Maryland, initially as a post-doc associate, and later as an expert consultant. In 1982, he was appointed as Professor at the Institute for Microbiology at the University of Heidelberg.

Over the years, he has received several honors, including the Leibniz Prize, the Louis-Jeantet Prize for Medicine, the German Prize for Technology and Innovation by the President of the Federal Republic of Germany, the Lower Saxony State Prize, as well as the German Federal Cross of Merit.

As President of the Max Planck Society, Peter Gruss holds numerous offices and functions. Among others, he is a member of the Senates of the Alliance of Scientific Organizations in Germany, the German Research Foundation (DFG), the German National Academy of Sciences Leopoldina, as well as of acatech, the German Academy of Science and Engineering. In addition, he is member of the Supervisory Boards of Siemens AG and Munich RE, as well as of the Advisory Board of Deloitte. He was appointed as a member of the "Innovation Dialogue" of the Federal Chancellery by Angela Merkel.

About the Max Planck Society

The Max Planck Society is Germany's most successful research organization. Since its establishment in 1948, no fewer than 17 Nobel laureates have emerged from the ranks of its scientists, putting it on a par with the best and most prestigious research institutions worldwide. The more than 13,000 publications each year in internationally renowned scientific journals are proof of the outstanding research work conducted at Max Planck Institutes -many of those articles are among the most-cited publications in their relevant fields.

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).

For further information please contact:

Roland Haefeli

Senior Vice President, Head of Investor Relations & Public Affairs

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

+41 61 565 62 62

+1 650 624 69 36

www.actelion.com

Press Release PDF


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

HUG#1608896

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
13 dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
24
08 dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
07 dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
09 dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14
07 dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14

Novo-rival spår effekt af ugentligt GLP-1 på linje med Ozempics

13-12-2017 13:30:09
Novo Nordisks store franske rival Sanofi forudser, at dens ugentlige GLP-1-analog, Efpeglenatid, har en effekt på langtidsblodsukkeret, der er på linje Novos nye ugentlige diabetes 2-middel Ozempic, som tilhører samme lægemiddelklasse.Det fremgår af en præsentation under et analytikerarrangement onsdag, hvor Sanofi fremlægger sin forsknings- og udviklingsstrategi for de kommende år.Sanofi indledte..

Novo-rival er på vej med nye studier i fedme og leversygdommen NASH

13-12-2017 09:56:25
Novo Nordisks store franske rival, Sanofi, vil ligesom Novo i de kommende år også fokusere på udviklingen af fedmemedicin og medicin til behandling af leversygdommen, NASH.Det fremgår af en pressemeddelelse i forbindelse med et analytikerarrangement onsdag, hvor Sanofi vil præsentere sin forsknings- og udviklingsstrategi for de kommende år.Sanofis udviklingsindsats inden for forretningsområdet, di..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får sin største ordre nogensinde i Indien - NY
2
Vestas rykker nærmere kæmpekontrakter i New Mexico og Texas
3
Aktier/tendens: Genmab og Vestas fortsætter i fokus
4
Vestas ejer mere end 5 pct. egne aktier efter opkøb
5
Onsdagens aktier: Genmab endnu engang til bunds i negativt marked

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
14. december 2017 05:04:15
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-14 05:04:15 - 2017-12-14 05:04:15 - 1 - Website: OKAY